科创板晚报|华秦科技签订2.5亿航空材料产品合同 中芯国际8英寸BCD工艺平台涨价10%

Group 1 - The State-owned Assets Supervision and Administration Commission (SASAC) emphasizes the need for central enterprises to promote strategic, specialized restructuring and high-quality mergers and acquisitions, focusing on sectors like new energy, aerospace, and quantum technology [1] - The U.S. plans to impose tariffs on China's semiconductor industry starting in 2027, which China firmly opposes, stating it disrupts global supply chains and harms both countries [1] - SMIC has notified customers of a 10% price increase for its 8-inch BCD process platform, driven by high demand for power chips in AI servers [2] Group 2 - Samsung and SK Hynix have raised the price of HBM3E by nearly 20% for the upcoming year, a rare occurrence before the launch of a new generation of HBM products [2] - Huayin Technology signed a framework procurement contract worth 254 million yuan for special functional materials for aircraft fuselages, which is expected to positively impact its performance [3] - TuoJing Technology's major shareholder, the National Integrated Circuit Fund, reduced its stake by 0.65% through block trading, affecting its ownership from 19.57% to 18.92% [4] Group 3 - Sany Heavy Energy plans to use up to 9.5 billion yuan of its own funds for entrusted wealth management in 2026, ensuring it does not affect its main business operations [4] - Pioneer Precision plans to use up to 250 million yuan of idle funds for entrusted wealth management, focusing on low-risk investment products [5] - Zhuhai Guanyu's shareholders plan to reduce their holdings by up to 3% for operational needs, with the reduction period set from January 20 to April 19, 2026 [6] Group 4 - Anjisi's subsidiary received three medical device registration certificates, enhancing its product line in the endoscopy field [7] - Yangguang Nuohuo signed a technical development contract for the STC008 injection project, securing a total of 500 million yuan in payments, including an initial payment of 50 million yuan [8] - Yuandong Bio's methylene blue injection has received FDA approval, marking its third product for international markets [9] Group 5 - Dize Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and brand image [9] - Chunfeng Huayu completed a multi-million A-round financing to accelerate product development and clinical progress in high-end medical devices [10] - Gesong Technology secured angel round financing to focus on embodied intelligence research and production [10]